No Data
No Data
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Novo Nordisk Bleeding Prevention Injection for Hemophilia Granted FDA Nod
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today